Evidence & regulatory context
- Mechanism
- ChEMBL not queried: PolySTAT is a synthetic peptide-functionalised haemostatic polymer, not a defined ChEMBL small molecule. ClinicalTrials.gov query 'PolySTAT OR fibrin cross-linking polymer' returned 0 hits, an explicit searched negative result. No human trial.
- Target
- Not recorded
- Injury models
- Haemorrhage/shock
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatHaemorrhage/shockControlledSprague-Dawleyn = 5 rats per treatment group across five groups (25 total)Intravenous, via jugular vein catheter15 mg/kg as a 10 mg/mL solutionImmediately after clamp release at the onset of bleeding
Model: Femoral artery injury with controlled haemorrhage and saline resuscitation: 3 mm longitudinal arteriotomy, catheter bleeds to set starting blood pressure at 40 to 50 mmHg, free bleeding for 15 min, then saline at 3 mL/min/kg to hold blood pressure above 60 mmHg up to 60 mL/kg
All PolySTAT-treated rats survived the protocol compared with 0 to 40 per cent for saline, PolySCRAM, albumin and factor XIIIa controls, with no rebleeding and up to eleven-fold less blood loss. PolySTAT rats needed about five-fold less saline (42 plus or minus 17 per cent of the maximum allowed vo…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.